Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06TGR
|
|||
| Former ID |
DNC005959
|
|||
| Drug Name |
8-(3-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one
|
|||
| Synonyms |
CHEMBL200685; 8-(3-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one; SCHEMBL5258643; WPUKKEMHTVGTFK-UHFFFAOYSA-N; BDBM50178081
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H17NO4
|
|||
| Canonical SMILES |
C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC(=CC=C4)O
|
|||
| InChI |
1S/C19H17NO4/c21-14-4-1-3-13(11-14)15-5-2-6-16-17(22)12-18(24-19(15)16)20-7-9-23-10-8-20/h1-6,11-12,21H,7-10H2
|
|||
| InChIKey |
WPUKKEMHTVGTFK-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA-dependent protein kinase catalytic (PRKDC) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Non-homologous end-joining | |||
| Cell cycle | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| Pathway Interaction Database | DNA-PK pathway in nonhomologous end joining | |||
| Coregulation of Androgen receptor activity | ||||
| Class I PI3K signaling events mediated by Akt | ||||
| BARD1 signaling events | ||||
| Reactome | Nonhomologous End-Joining (NHEJ) | |||
| WikiPathways | DNA Damage Response | |||
| Non-homologous end joining | ||||
| FAS pathway and Stress induction of HSP regulation | ||||
| Cytosolic sensors of pathogen-associated DNA | ||||
| Retinoblastoma (RB) in Cancer | ||||
| Prostate Cancer | ||||
| Double-Strand Break Repair | ||||
| Cell Cycle | ||||
| miRNA Regulation of DNA Damage Response | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.